Table 2.

RRs for selected cancers, by lifetime exposure-days to carbofuran among AHS (1993–1997) applicators with nonexposed and low-exposed groups as referents.

Lifetime exposure daysa	Cases (n)	Nonexposed referent RR (95% CI)	Low-exposed referent RR (95% CI)
All cancers
0	1,012	1.0
> 0–9	151	0.95 (0.80–1.14)	1.0
10–39	115	0.95 (0.78–1.15)	1.00 (0.78–1.27)
40–109	80	1.05 (0.83–1.33)	1.11 (0.83–1.49)
> 109	51	0.94 (0.70–1.26)	0.96 (0.67–1.37)
Trendb		0.79	0.94
Lymphatic–hematopoietic cancers
0	103	1.0
> 0–9	11	0.68 (0.36–1.30)	1.0
10–39	10	0.82 (0.42–1.60)	1.05 (0.44–2.51)
40–109	11	1.38 (0.72–2.65)	1.56 (0.62–3.92)
> 109	5	0.86 (0.34–2.23)	0.77 (0.23–2.57)
Trendb		0.93	0.74
Non-Hodgkin lymphoma
0	44	1.0
> 0–9	6	0.77 (0.31–1.86)	1.0
10–39	7	1.27 (0.55–2.91)	1.33 (0.44–4.02)
40–109	7	1.40 (0.59–3.30)	1.08 (0.31–3.74)
Trendb		0.40	0.94
Colon
0	80	1.0
> 0–9	10	0.88 (0.45–1.72)	1.0
10–39	9	0.99 (0.49–2.02)	1.03 (0.41–2.56)
40–109	5	0.84 (0.33–2.12)	0.77 (0.25–2.42)
> 109	6	1.34 (0.54–3.31)	1.16 (0.36–3.71)
Trendb		0.68	0.85
Lung
0	98	1.0
> 0–9	6	0.42 (0.18–0.97)	1.0
10–39	8	0.68 (0.33–1.43)	1.61 (0.55–4.69)
40–109	9	1.09 (0.54–2.22)	2.54 (0.85–7.67)
> 109	8	1.38 (0.63–2.99)	3.05 (0.94–9.87)
Trendb		0.46	0.07
Prostate
0	372	1.0
> 0–9	85	1.30 (1.01–1.66)	1.0
10–39	48	0.99 (0.73–1.35)	0.79 (0.55–1.13)
40–109	29	1.03 (0.70–1.53)	0.86 (0.55–1.36)
> 109	17	0.88 (0.53–1.47)	0.73 (0.41–1.31)
Trendb		0.70	0.34

Rate ratios adjusted for age, sex, education, family history of cancer, smoking, alcohol, year of enrollment, state of residence, and exposure to EPTC, fonofos, trichlorofon, chlorpyrifos, and permethrin.

^aYears of use × days of use per year.

^bp-Value for trend test.